Nabriva Therapeutics PLC
Change company Symbol lookup
Select an option...
NBRV Nabriva Therapeutics PLC
DXCM DexCom Inc
CSRLF CSR Ltd
LGIH LGI Homes Inc
ARI Apollo Commercial Real Estate Finance Inc
D Dominion Energy Inc
QTS-A QTS Realty Trust Inc
ICHR Ichor Holdings Ltd
AMRC Ameresco Inc
AVID Avid Technology Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Growth
Based in Ireland
Company profile

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Closing Price
$0.776
Day's Change
0.016 (2.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.7789
Day's Low
0.7503
Volume
(Light)
Volume:
2,205,316

10-day average volume:
5,953,552
2,205,316

Company Profile

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
12.95x
Price/Book (MRQ)
3.68x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

July 2020
Current Month
5.3M
Previous Month
6.3M
Percent of Float
5.68%
Days to Cover
2.0595 Days

Share Information

NBRV is in a share class of common stock
Float
141.8M
Shares Outstanding
143.0M
Institutions Holding Shares
53
23.21%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Daniel D. Burgess
  • Steven P. GelonePres.
  • Theodore R. SchroederCEO
  • Gary L. SenderCFO
  • Robert L. CrottyCounsel

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.